Neuropathix, Inc.
https://neuropathix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neuropathix, Inc.
Start-Up Quarterly Statistics, Q3 2012
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
Recent Tech Transfer Deals, September 2012
START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Spectranetics Delivers on Laser's Promise
After a bright promise in the early 1980s, cardiac lasers fell out of favor due to high complication rates and equivocal clinical results. Laser pioneer Spectranetics faced those problems and more, causing the company to languish in the 1990s. Now its back, with a new marketing partner, US Surgical, in a hot new area, TMR, and a strategy that allows the company to spread its risk.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- TYG Solutions Corp.
- KannaLife Sciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice